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Although a large number of mutations causing malfunction of complex I (NADH:ubiquinone oxidoreductase) of the OXPHOS system is now
known, their cell biological consequences remain obscure. We previously showed that the bradykinin (Bk)-induced increase in mitochondrial
[ATP] ([ATP]M) is significantly reduced in primary skin fibroblasts from a patient with an isolated complex I deficiency. The present work
addresses the mechanism(s) underlying this impaired response. Luminometry of fibroblasts from 6 healthy subjects and 14 genetically
characterized patients expressing mitochondria targeted luciferase revealed that the Bk-induced increase in [ATP]M was significantly, but to a
variable degree, decreased in 10 patients. The same variation was observed for the increases in mitochondrial [Ca2+] ([Ca2+]M), measured with
mitochondria targeted aequorin, and cytosolic [Ca2+] ([Ca2+]C), measured with fura-2, and for the Ca
2+ content of the endoplasmic reticulum (ER),
calculated from the increase in [Ca2+]C evoked by thapsigargin, an inhibitor of the ER Ca
2+ ATPase. Regression analysis revealed that the increase
in [ATP]M was directly proportional to the increases in [Ca
2+]C and [Ca
2+]M and to the ER Ca
2+ content. Our findings provide evidence that a
pathological reduction in ER Ca2+ content is the direct cause of the impaired Bk-induced increase in [ATP]M in human complex I deficiency.
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Abbreviations: [ATP]M, ATP concentration in the mitochondrial matrix;
[Ca2+]C, cytosolic free Ca
2+ concentration; [Ca2+]M, free Ca
2+ concentration in
the mitochondrial matrix; OXPHOS, oxidative phosphorylation; IMM, inner
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Mitochondrial and cellular (patho)physiology are tightly
interconnected at the level of ATP homeostasis, reactive
oxygen species generation, Ca2+ handling and apoptosis [1].
Each aspect of mitochondrial functioning critically depends on
the ability of this organelle to maintain a sufficiently large
potential difference (Dw) across the inner mitochondrial
membrane (IMM). Under normal conditions, this potential
difference is generated by the combined action of the
complexes I to IVof the oxidative phosphorylation (OXPHOS)
system. The complexes I, III and IV use the energy stored in
NADH and FADH2 to expel protons from the mitochondrial
matrix into the intermembrane space. The electrochemical
proton gradient created in this way drives the synthesis of ATP1762 (2006) 115 – 123
http://www
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complex V of the OXPHOS system. Under conditions that the
complexes I to IVare unable to maintain Dw, e.g., as a result of
limited NADH supply or defects in one or more of these
complexes, the F0F1–ATPase may work in the reverse mode to
expel protons at the cost of glycolytic ATP imported by the
adenine nucleotide translocase (ANT).
Work over the past years has shown that extracellular stimuli
that act through inositol 1,4,5-trisphosphate (IP3) to release
Ca2+ from the endoplasmic reticulum (ER) cause a rapid
increase in mitochondrial ATP concentration ([ATPM]) [2–4]. It
is generally believed that this mechanism serves to fuel the
ATPases involved in the rapid extrusion of Ca2+ ions from the
cytosolic compartment [5]. The same studies showed a parallel
increase in mitochondrial Ca2+ concentration ([Ca2+]M). In
contrast with the classic respiratory control theory, which states
that the rate of mitochondrial ATP production is solely
determined by the availability of ADP [6], the above findings
have led to the new idea that the increase in [Ca2+]M acts at
several points in the mitochondrial ATP production process to
evoke a rapid increase in mitochondrial ATP production [7].
Indeed, mitochondrial Ca2+ uptake has been demonstrated to
increase the activity of pyruvate dehydrogenase, NAD+-
dependent isocitrate dehydrogenase and 2-oxoglutarate dehy-
drogenase, thereby enhancing the supply of NADH and FADH2
to the OXPHOS system [8–11]. Moreover, evidence has been
provided that Ca2+ can stimulate the activity of complex V in
homogenates of cultured skin fibroblasts [12] and heart and
skeletal muscle biopsy material of healthy children [6,13]. As
far as the increase in [Ca2+]C is concerned, recent work suggests
that the aspartate/glutamate carrier (AGC), which is important
in the aspartate/malate shuttle that imports NADH into the
mitochondrion, is stimulated by Ca2+ on the external side of the
IMM [14]. Accordingly, overexpression of this carrier in
Chinese hamster ovary cells increased the amplitude of the
agonist-induced peak increase in [ATP]M, independent from the
activation of the Ca2+-sensitive matrix dehydrogenases [15]. In
addition, it has been suggested that [Ca2+]C increases the
activity of the adenine nucleotide translocase (ANT), involved
in the electrogenic exchange of ADP3 for ATP4 across the
IMM [16]. These findings suggest an independent stimulatory
action of Ca2+ on both the matrix (matrix dehydrogenases and
complex V) and cytosolic side (AGC and ANT) of the IMM.
Respiratory chain dysfunction forms the basis of severe
clinical syndromes, presenting either at birth or in early
childhood, frequently affecting brain, heart and skeletal
muscle [17]. Among these disorders, isolated complex I
deficiency (OMIM 252010) is the most frequently encoun-
tered enzyme defect [18,19]. Structurally, complex I (NAD-
H:ubiquinone oxidoreductase; E.C. 1.6.5.3) consists of 46
subunits, seven of which are encoded by the mitochondrial
DNA and the remainder by the nuclear genome [20]. In
addition to defects in the mitochondrial DNA, mutations in
nuclear genes (NDUFV1, NDUFS1, NDUFS2, NDUFS3,
NDUFS4, NDUFS6, NDUFS7, NDUFS8) have been shown
to be associated with isolated human complex I deficiency
[21–24].In order to enhance our understanding of the pathophysi-
ology of disorders of the human OXPHOS system, we study
genetically characterized patient skin fibroblasts [17]. In doing
so, we recently demonstrated that fibroblasts harbouring
pathological mutations in nuclear complex I genes displayed
a reduced amount of fully assembled complex I [25].
Moreover, we showed that Dw was slightly (¨15%) decreased
in fibroblasts from a patient with Leigh disease carrying a
homozygous missense mutation (G364A) in the nuclear
NDUFS7 gene ([4]; P11 of the present study). Importantly, it
was observed that the peak increases in [Ca2+]C, [Ca
2+]M and
[ATP]M evoked by the Ca
2+ mobilizing agonist bradykinin
(Bk) were significantly reduced in these patient fibroblasts. To
our surprise, however, complete restoration of the Bk-induced
increases in [Ca2+]M and [ATP]M, but not [Ca
2+]C, was
achieved using the inhibitor of mitochondrial Na+–Ca2+
exchange, CGP37157 (1 AM, 2 min), suggesting that the small
decrease in Dw was not the underlying cause of the observed
reduction in Bk-stimulated mitochondrial Ca2+ accumulation
and ensuing ATP production.
The present study, carried out in a collection of skin
fibroblasts from 6 healthy subjects and 14 patients with an
isolated complex I deficiency, demonstrates that a reduced Ca2+
content of the ER forms the basis of the impaired agonist-
induced increase in mitochondrial ATP production in human
complex I deficiency. This knowledge is of importance for the
development of new strategies aimed at counterbalancing the
pathological consequences of this deficiency.
2. Materials and methods
2.1. Cell lines
Fibroblasts were obtained, following informed parental consent, from skin
biopsies of 6 healthy subjects of different age (C1–C3: adults, C4–C6:
children) and 14 patients (marked P1–P14; all children between the age of 0–5
years) in whom an isolated NADH:ubiquinone oxidoreductase (complex I; EC:
1.6.5.3) deficiency was confirmed in muscle tissue as well as in cultured
fibroblasts (Table 1). This collection of cells harboured disease-causing
mutations in the NDUFS1 (one patient), NDUFS2 (5 patients; [26]), NDUFS4
(4 patients; [27,28]), NDUFS7 (one patient; [29]), NDUFS8 (one patient) or
NDUFV1 (two patients; [30]) genes of complex I. Complex I activity
measurements were performed in a mitochondria-enriched fraction from
cultured skin fibroblasts as described previously [18]. The activity of the
complex was normalized against that of complex IV (cytochrome c oxidase),
which was measured in the same fraction, and expressed as percentage of the
lowest control (0.11 mU/mU cytochrome c oxidase; [18]). Fibroblasts were
cultured in M199 medium containing 5 mg/l Tween 20, supplemented with
10% (v/v) fetal calf serum, 100 IU/ml penicillin and 100 IU/ml streptomycin.
2.2. Expression of mitochondria targeted luciferase and
aequorin
Given the resilience of human skin fibroblasts to classical transfection
methods, we adapted the baculovirus expression system (normally employed
for protein production in Spodoptera frugiperda 9 insect cells) for use in
mammalian cells. A modified baculovirus transfer vector (BVTV) was
constructed by removing the herpes simplex virus thymidine kinase poly-
adenylation signal and the p10- and polyhedron promoters from the pFastBaci
Dual vector (Invitrogen, Breda, The Netherlands). These sequences were
replaced by the coding region of a cytomegalovirus promoter digested from the
pcDNA1 vector (Invitrogen).
Table 1
Fibroblast cell lines and bradykinin-induced effects
Cell line Affected
gene
Mutation CI
activ.a
Peak
[ATP]M
b
Peak
[Ca2+]M
b
Basal
[Ca2+]C
b
Peak
[Ca2+]C
b
t2
[Ca2+]C
c
ER Ca2+
contentd
DNA Protein
C pooled None None None 101T5 (49) 100T2 (18) 100T2 100T2 100T2 (114) 100T4 (55)
C1 (#5120) None None None 113 100T2 (31) 100T2 (11) 104T4 100T3 105T5 (29) 97T6 (20)
C2 (#5118) None None None 103 110T7 (5) 103T8 (4) 95T3 100T4 100T4 (30) 102T8 (20)
C3 (#5119) None None None 105 101T6 (3) 96T2 (3) 106T6 104T4 100T4 (31) 102T6 (15)
C4(#mw26) None None None 152 97T7 (4) n.d. n.d. n.d. n.d. n.d.
C5 (#mw28) None None None 97 98T7 (3) n.d. n.d. n.d. n.d. n.d.
C6 (#mw33) None None None 220 101T6 (3) n.d. n.d. n.d. n.d. n.d.
P1 (#6173)e NDUFS1 G1854A/C1668T R557X/D618N 31 77T9 (7) 86T4 (4) 101T3 91T2 136T6 (16) 82T4 (29)
P2 (#4605) NDUFS2 T1237C S413P 40 72T4 (3) n.d. 109T6 93T5 130T10 (22) n.d.
P3 (#5067) NDUFS2 C686A P229Q 36 78T7 (11) 87T3 (4) 104T4 101T5 142T9 (20) 94T4 (70)
P4 (#5170) NDUFS2 G683A R228Q 39 102T7 (5) 95T1 (4) 100T3 97T4 102T7 (25) 95T2 (23)
P5 (#7276)e NDUFS2 26 60T2 (6) 87T1 (5) 94T2 91T2 146T4 (27) 82T2 (33)
P6 (#7277)e NDUFS2 87 100T6 (5) 106T3 (5) 98T2 100T3 98T3 (18) 100T2 (28)
P7 (#4608) NDUFS4 AAGTC471 ins K158fs 75 97T6 (7) 97T4 (4) 103T3 108T4 110T6 (31) 96T4 (44)
P8 (#4827) NDUFS4 C316T R106X 58 33T5 (3) n.d. 109T5 82T4 169T12 (23) n.d.
P9 (#5260) NDUFS4 C316T R106X 36 48T10 (5) 79T1 (4) 96T1 84T2 160T10 (18) 77T4 (40)
P10 (#5737)e NDUFS4 C202G/G203 del VPEEHI67/VEKSIstop 53 86T4 (5) 96T3 (4) 99T2 93T2 126T6 (4) 87T6 (22)
P11 (#5175) NDUFS7 G364A V122M 68 57T5 (3) 76T5 (3) 109T5 80T4 164T10 (21) 73T2 (16)
P12 (#6603)e NDUFS8 C280T R94C 18 74T1 (6) 89T3 (5) 106T6 91T4 134T6 (20) 85T6 (17)
P13 (#5866) NDUFV1 C175T/C1268T R59X/T423M 64 67T4 (4) 86T0.2 (5) 87T1 90T2 140T5 (28) 87T3 (42)
P14 (#5171) NDUFV1 C175T/C1268T R59X/T423M 73 93T6 (7) 99T1 (4) 106T5 96T5 112T7 (20) 96T3 (48)
Values significantly different from control C1 ( P <0.05) are depicted in bold. Numerals between brackets indicate the number of coverslips (peak [ATP]M and peak
[Ca2+]M) or cells (t2, ER Ca
2+ content; for basal [Ca2+]C and peak [Ca
2+]C see column t2). All values are expressed as percentage of the value obtained with C1 on
the same day; n.d., not determined.
a Activity of complex I expressed relative to complex IV and as percentage of the lowest control [18].
b Maximal increases obtained with 1 AM bradykinin.
c Half-time of the decay phase of the bradykinin-induced [Ca2+]C transient.
d Peak increase in [Ca2+]C following application of 10 AM BHQ.
e Manuscript in preparation.
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contained the 25-aa presequence and the first 8 aa of subunit VIII of
cytochrome c oxidase, the 9-aa HA1 epitope tag, and the whole photoprotein
[3]. This construct was digested from the AdCMVmtLuc vector [31] with EcoRI
and XbaI and inserted behind the CMV promoter using the EcoRI and XbaI
restriction sites of the BVTV to yield the BVTVmtLUC construct. The wild-type
mitochondria-targeted aequorin cDNA was digested from the AdCMVmAq
vector [31] with KpnI and XbaI and ligated behind the CMV promoter using
the KpnI and XbaI restriction sites of the BVTV to generate the BVTVmtAEQ
construct.
To create viruses, competent DH10bac Escherichia coli cells, harbouring the
baculovirus genome (bacmid) and a transposition helper vector, were trans-
formed with the BVTVmtLUC or the BVTVmtAEQ construct. On transition
between the Tn7 sites in the transfer vector and the bacmid, recombinant bacmids
were selected and isolated [32]. Subsequently, insect Sf9 cells were transfected
with recombinant bacmids using Cellfectin. After 3 days, the recombinant
baculoviruses were harvested and used to infect Sf9 cells at a multiplicity of
infection of 0.1. Four days after infection, the amplified viruses were harvested.
To express mitochondria-targeted luciferase (mtLUC) or aequorin (mtAEQ)
in human skin fibroblasts, approximately 20,000 cells were seeded on a 14 mm
coverslip and after 4 h cells were infected with viruses (5% v/v in medium
M199, containing 25 mM HEPES, 10% v/v FCS, 100 IU/ml penicillin and 100
IU/ml streptomycin). Following this, cells were cultured for another 48 h in the
presence of 1.75 mM sodium butyrate.
2.3. Luminescence monitoring of mtLUC and mtAEQ
Luminescence of mtLUC was monitored continuously from the total
coverslip using a custom build setup consisting of a light shielded low-noise
photomultiplier tube (PMT) with a built-in H7360-1 amplifier-discriminator
(Hamamatsu Photonics K. K. Shizuoka-Ken, Japan). The output voltage of
the PMT was continuously monitored using a PCI-6601 photon countingboard (National Instruments, Austin, TX) and custom PC-software developed
by Drs. S.P. Srinivas and W. van Driessche (Laboratory of Physiology, K.U.
Leuven, Belgium). Cells were continuously superfused (3 mlImin1) with
HEPES–Tris buffer (132 mM NaCl, 4.2 mM KCl, 1 mM MgCl2, 5.5 mM d-
glucose, 10 mM HEPES, 1 mM CaCl2, pH 7.4), containing 5 AM beetle
luciferin (Promega, Madison, WI) at 37 -C. Light output was integrated
during 1 s and recorded at intervals of 2 s. With these settings, typical light
output from a coverslip ranged between 1000 and 25,000 countsIs1 whereas
the background signal was 10 countsIs1. For visualization and quantitative
analysis, recordings were smoothed off-line using a moving average
algorithm with a window size of 6 s.
The above PMT system was also used to monitor mtAEQ luminescence.
Prior to measurements, mtAEQ was reconstituted with 5 AM native coelenter-
azine (Promega) in serum-freeM199medium for 1 h at 37 -C.When themtAEQ/
coelenterazine complex binds three Ca2+ ions, coelenterazine is oxidized to
coelenteramide, with a concomitant release of CO2 and blue light. Light output
was integrated during 1s and recorded at 1 s intervals. Each experiment was
calibrated by lysing the cells with 100 AM digitonin in the presence of 10 mM
CaCl2 to determine the total aequorin pool. MtAEQ photon emission was
converted off-line into [Ca2+] values, using a computer algorithm based on the
Ca2+ response curve of wild-type aequorin, as described previously [33].
2.4. Video-imaging of cytosolic [Ca2+] with fura-2
To monitor changes in cytosolic [Ca2+], fibroblasts, seeded on < 24 mm
coverslips, were loaded with 3 AM fura-2/AM for 25 min at 37 -C in M199
medium. After loading, cells were washed twice and allowed to equilibrate for
another 10 min. Next, cells were incubated with HEPES–Tris buffer (pH 7.4)
and placed in a temperature-controlled (37 -C) superfusion chamber attached to
the stage of an inverted microscope (Axiovert 200M, Carl Zeiss, Jena, Germany)
equipped with a40, 1.3 NA Plan NeoFluar objective. Fura-2 was alternatingly
excited at 340 and 380 nm using a monochromator (Polychrome IV, TILL
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430DCLP dichroic mirror (Omega Optical Inc., Brattleboro, VT) through a
510WB40 emission filter (Omega Optical Inc.) onto a CoolSNAP HQ
monochrome CCD-camera (Roper Scientific, Vianen, The Netherlands). The
integration time of the CCD camerawas set at 100ms and a sampling interval of 1
s was used. All hardware was controlled with Metafluor 6.0 software (Universal
Imaging Corporation, Downingtown, PA). At the end of each experiment, cells
were scraped off the coverslip to correct for background fluorescence. The
kinetics with which the fura-2 fluorescence emission ratio (R) decreased was
fitted to a mono-exponential function:R(t)=RM Ie
k It +RP, whereRM represents
the maximal fura-2 ratio, k is the decay constant (in s) and RP is an offset being
the post-stimulatory level to which R declines [34,35]. From k, the halftime (t2)
was calculated using the equation: t2 (s)=ln(0.5) k [4].
2.5. Chemicals and data analysis
Culture material was obtained from Invitrogen (Breda, The Netherlands)
and all other reagents were from Sigma (St. Louis, MO). Cellfectin, competent
DH10bac E. coli cells, and all enzymes for DNA cloning were purchased from
Invitrogen. Numerical data were visualized using Origin Pro 6.1 (OriginLab
Corp., Northampton, MA) and values from multiple experiments were
expressed as averageTS.E. Statistical significances were assessed by Student’s
t-test. During curve fitting, Pearson’s correlation coefficient R was used as an
estimate of the population correlation coefficient. Values of 1 and +1 indicate
a perfect negative and positive linear relationship between the two variables,
respectively [36]. When fitting was performed for a dataset obtained from
multiple experiments, the contribution of each average data point to the fitted
equation was weighed (weight=1/(S.E.)2).
3. Results
Malfunction of complex I, the first and largest complex of
the respiratory chain, is the most commonly encountered defect
of the mitochondrial OXPHOS system. In a previous study we
demonstrated that the Ca2+ mobilizing agonist bradykinin (Bk)
induced a significantly lower increase in cytosolic [Ca2+]
([Ca2+]C) in non-immortalized, primary skin fibroblasts in 4 out
of 8 patients with an isolated complex I deficiency associated
with mutations in nuclear-encoded subunits of this complex
[4]. Detailed analysis of a single patient (P11; Table 1) revealed
that this lower increase in [Ca2+]C was paralleled by a reduced
increase in mitochondrial [Ca2+] ([Ca2+]M) and [ATP]Fig. 1. Lack of correlation between bradykinin-increase in [ATP]M and enzymatic
deficiency. (A) Bradykinin (1 AM) transiently increased the intramitochondrial [ATP
were infected with a baculovirus containing the cDNA of mitochondria targeted lu
application of the hormone and onset of the increase in [ATP]M was ¨25 s. (B) The b
(black bar), was similar in 6 controls (grey bars) but significantly reduced in 10 out
[ATP]M, measured in living cells, versus the enzymatic activity of complex I, determ
patient and/or control cell line numbers. Statistical significance is indicated by *P <([ATP]M). Intriguingly, this patient displayed also a lower ER
Ca2+ content, which suggested a causative link with the
reduced peak increase in [ATP]M. Here, we investigated the
validity of this hypothesis by measuring the Bk-induced
changes in [ATP]M in primary skin fibroblasts from a cohort
of 6 healthy control subjects (C1–C6) and 14 patients with an
isolated complex I deficiency (P1–P14; Table 1).
3.1. Bradykinin increases [ATP]M to a variable degree in
complex I deficient patient fibroblasts
Fibroblasts expressing mitochondria targeted luciferase
(mtLUC) were challenged with a high concentration of Bk
(1 AM) to achieve a maximal increase in [ATP]M [4].
Immunocytochemical analysis confirmed the mitochondrial
localization of mtLUC and pretreatment of the cells with the
mitochondrial ATP-synthase inhibitor oligomycin (10 AM, 5
min) virtually abolished the Bk-induced increase in [ATP]M
(not shown). Fig. 1A shows that in both control and patient
fibroblasts the hormone evoked a transient increase in [ATP]M
starting at ¨25 s (grey bar) after the onset of stimulation (see
also, [3,4]). Fibroblasts from the control cell line C1
displayed a peak increase in [ATP]M of 28T1.5% (n =31).
In each measurement, the value obtained with this cell line
was set at 100%, to which all other values were related.
Importantly, this value did not significantly differ between the
six control cell lines used in this study (C1–C3: adults; C4–
C6: children; Fig. 1B and Table 1). Moreover, this value did
not alter during 13 cell passages (not shown). As exemplified
for P9 in Fig. 1A, the Bk-induced peak increase in [ATP]M
was significantly, but to a variable degree, decreased in
fibroblasts from 10 out of 14 patients (Fig. 1B and Table 1).
The luminescence traces obtained from the patients P4, P6,
P7 and P14 did not differ from control. Analysis of the rate of
increase of [ATP]M, which was also significantly slowed
down in these 10 patient cell lines, revealed a linear
correlation with the peak increase in [ATP]M (data not
shown).activity of complex I in fibroblasts from patients with an isolated complex I
] ([ATP]M) in a typical control (C1) and patient fibroblast (P9) cell line. Cells
ciferase (mtLUC) and monitored by luminometry. The time delay (dt) between
radykinin-induced peak increase [ATP]M, expressed as percentage of that in C1
of 14 patients (open bars). (C) Plot of the bradykinin-induced peak increase in
ined in a mitochondrial enriched fraction. In panels B and C, numerals designate
0.05 and ***P <0.001.
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bradykinin-induced increase in [ATP]M
Complex I activity measurements were performed in a
mitochondrial enriched fraction from cultured skin fibroblasts.
The activity of the complex was normalized against that of
complex IV (cytochrome c oxidase), which was measured in
the same fraction, and expressed as percentage of the lowest
control (0.11 mU/mU cytochrome c oxidase; [18]). Importantly,
all patients included in this study had a normal complex IV
activity (data not shown). Plotting of the normalized complex I
activities against the normalized peak increases in [ATP]M
displayed the absence of any correlation between these two
parameters in human complex I deficiency (Fig. 1C; P=0.30).
3.3. Positive correlation between the peak increases in [ATP]M
and [Ca2+]M
Because of the absence of any correlation between complex
I activity and peak increase in [ATP]M, we next investigated the
possibility of alterations in mitochondrial Ca2+ handling being
the underlying cause of the impaired ATP response in Bk-
stimulated patient fibroblasts. To this end, fibroblasts were
infected with a baculovirus containing the cDNA for mito-
chondria targeted aequorin (mtAEQ). Fig. 2A shows that in
both control and patient fibroblasts, Bk increased [Ca2+]M
instantaneously. In the control cell line C1, the peak increase in
[Ca2+]M amounted to 5.7T0.2 AM (n =11). In each measure-
ment, the value obtained with this control was set at 100%, to
which all other values were related. This value did not differ
between three control cell lines (C1–C3), whereas it was
significantly decreased in 7 of the 12 patient cell lines testedFig. 2. Positive correlation between the bradykinin-induced peak increases in [ATP]M
transiently increased the intramitochondrial [Ca2+] ([Ca2+]M) in a typical control
baculovirus containing the cDNA of mitochondria targeted aequorin (mtAEQ) for
plotted as a function of the peak increase in [Ca2+]M for 12 complex I deficient patien
with control cell line C1. Data were fitted to a Hill equation (thick line; details are g
represent the 95% prediction limit of the fit. Statistical significances are given in T(Fig. 2B and Table 1). Again, the luminescence traces obtained
from the patients P4, P6, P7 and P14 and, in addition, P10 did
not differ from control. Previous analysis of the dependence of
the peak increase in [ATP]M from the peak increase in [Ca
2+]M
revealed a sigmoid correlation in histamine-stimulated HeLa
cells [3]. Fig. 2B shows the same dependence ( y =ymaxIx
n/
(kn+xn)) in our cohort of patient cell lines (R =0.92,
k =78T0.07%, n =11T0.11).
3.4. Positive correlation between the peak increases in
[Ca2+]M and [Ca
2+]C
To determine whether the reduced peak increase in [Ca2+]M in
patient fibroblasts was due to a reduced increase in [Ca2+]C,
fibroblasts were loaded with the cytosolic Ca2+ indicator fura-2
and subjected to digital imaging microscopy. Both control and
patient fibroblasts displayed an instantaneous increase in
[Ca2+]C upon stimulation with Bk (Fig. 3A). In C1 fibroblasts,
this increase was 3.8T0.2 (n =29) times baseline. In each
experiment, the value obtained with this control was set at 100%,
to which all other values were related. As exemplified for P9, the
peak increase in [Ca2+]C was markedly reduced in 8 out of 14
patient cell lines (Figs. 3B and Table 1). No significant decrease
was observed for P4, P6, P7 and P14 and, in addition, P2 and P3
(Fig. 3B). Regression analysis revealed a positive correlation
between the Bk-induced increase in [Ca2+]C and [Ca
2+]M
(R =0.83, P <0.01). As exemplified for P9, the rate of decay
of [Ca2+]C was markedly reduced in 10 out of 14 patient cell
lines (Figs. 3C and Table 1). The rate of [Ca2+]C decay was fitted
monoexponentially and the obtained half-times were used for
statistical evaluation. The half-time calculated for C1 fibroblasts
was 13.2T1.7 s (n =29). Again, no significant decrease wasand [Ca2+]M in complex I-deficient patient fibroblasts. (A) Bradykinin (1 AM)
(C1) and patient fibroblast (P9) cell line. Fibroblasts were infected with a
monitoring by luminometry. (B) Bradykinin-induced peak increase in [ATP]M
t cell lines. Both parameters were expressed as percentage of the value obtained
iven in the text). Numerals designate patient cell line numbers and dotted lines
able 1.
Fig. 3. Positive correlation between the bradykinin-induced peak increases in [Ca2+]M and [Ca
2+]C and the bradykinin-induced increase in [ATP]M and the cytosolic
Ca2+ removal rate in complex I deficient patient fibroblasts. (A) Bradykinin (1 AM) transiently increased the cytosolic [Ca2+] ([Ca2+]C) in a typical control (C1) and
patient fibroblast (P9) cell line. Cells were loaded with the fluorescent Ca2+ indicator fura-2 and monitored by digital imaging microscopy. (B) The peak increases in
[Ca2+]M and [Ca
2+]C are linearly correlated. (C) The decay phase of the [Ca
2+]C transient was fitted to a monoexponential equation, yielding a half-time that was a
linear function of peak increase in [ATP]M. All parameters were expressed as percentage of the value obtained with the control cell line C1. Numerals designate
patient cell line numbers. Statistical significances are given in Table 1.
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correlation between the half-time of cytosolic Ca2+ removal and
the Bk-induced peak increase in [ATP]M (R =0.97,
P <0.0001). Taken together, these findings show that a reduction
in peak [Ca2+]C increase underlies the reduced peak increases in
[Ca2+]M and [ATP]M in Bk-stimulated patient fibroblasts.
3.5. Positive correlation between the peak increase in [Ca2+]C
and the ER Ca2+ content
Measurements performed in the absence of extracellular Ca2+
indicated that Bk increases [Ca2+]C primarily by stimulating the
release of Ca2+ from the endoplasmic reticulum (ER) [4].
Therefore, the reduced Bk-induced increase in [Ca2+]C observedFig. 4. Positive correlation between the resting ER Ca2+ content and the bradykinin
fibroblasts. (A) Fura-2-loaded control and patient fibroblasts were treated with the S
digital imaging microscopy. The inhibitor caused a rapid and transient increase in [C
transient was taken as a measure of the ER Ca2+ content. (B) Linear correlation betw
(C) Linear correlation between the ER Ca2+ content and the bradykinin-induced pea
significances are given in Table 1.in fibroblasts from 8 out of 14 patients suggested a decrease in
either ER Ca2+ content or efficiency of the IP3-operated Ca
2+
release mechanism. Here, we investigated the first possibility by
determining the amount of Ca2+ that leaks out of this organelle
after inhibition of the sarco(endo)plasmic reticulum Ca2+-
ATPase (SERCA) with BHQ. The measurements were per-
formed in the absence of extracellular calcium (no Ca2+ added
and 0.5 mMEGTA present). BHQ (10 AM) transiently increased
[Ca2+]C in both control and patient fibroblasts (Fig. 4A). As
exemplified for P9, the BHQ-induced peak increase in [Ca2+]C
was significantly lower in 7 out of 12 patient cell lines. Also, in
this case, the values obtained for P4, P6, P7 and P14 and, in
addition, P3 did not differ from control. Regression analysis
revealed a positive correlation between the ER Ca2+ content and-induced peak increases in [Ca2+]C and [ATP]M in complex I deficient patient
ERCA inhibitor BHQ (10 AM) and the changes in [Ca2+]C were monitored by
a2+]C in both the control (C1) and patient (P9) cell line. The peak value of the
een the ER Ca2+ content and the bradykinin-induced peak increase in [Ca2+]C.
k increase in [ATP]M. Numerals designate patient cell line numbers. Statistical
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R =0.92; P <0.01) and [ATP]M (Fig. 4C; R =0.87; P <0.001).
4. Discussion
Human complex I (NADH:ubiquinone oxidoreductase) de-
ficiency is associated with a wide variety of clinical symptoms,
of which the underlying cell biological causes are poorly
understood [17]. Here, we focused on possible alterations in the
process of Ca2+-stimulated mitochondrial ATP production in
primary fibroblasts from complex I deficient patients harbour-
ing mutations in nuclear-encoded subunits of this complex
[21]. We show that the Ca2+ mobilizing agonist Bk increases
[ATP]M to a variable degree between complex I deficient
patients. Moreover, we show that the degree to which the Bk-
induced increase in [ATP]M is decreased depends directly on
the Ca2+ content of the ER. As to the physiological relevance
of the Ca2+-stimulated increase in mitochondrial ATP produc-
tion it has been proposed that it allows rapid balancing of
energy demand to supply during agonist stimulation [1].
One of the intriguing findings of the present study is that the
regression line for the amplitude of the Bk-induced increase in
[Ca2+]C versus [Ca
2+]M was not significantly different from the
line of identity for the cohort of 12 complex I deficient patients
(Fig. 3B). This indicates that the reduction of the Bk-induced
increase in [Ca2+]M is primarily due to the reduction of the Bk-
induced increase in [Ca2+]C. An important implication of this
finding is that it suggests that the electrical component of the
driving force for mitochondrial Ca2+ uptake is largely unaltered
in complex I deficient fibroblasts. This is in agreement with our
previous work showing only a small decrease in Dw in P11 of
the present study [4]. Another intriguing finding of this study is
that neither the Bk-induced increase in [Ca2+]C, [Ca
2+]M or
[ATP]M, nor the ER Ca
2+ content showed any correlation with
the activity of complex I, which was determined in a
mitochondrial enriched preparation and shown to be signifi-
cantly decreased in all 14 patient fibroblast cell lines. This
suggests that in intact patient fibroblasts, complex I does not
significantly contribute to the Ca2+-stimulated increase in
[ATP]M. This idea is supported by our recent demonstration
that the Bk-induced increase in [ATP]M could be fully restored
in complex I deficient patient fibroblasts following normaliza-
tion of the Bk-induced increase in [Ca2+]M [4].
Although malfunctioning of complex I is generally thought
to result in a decrease in Dw, our experimental data indicate
that this is not the case. The mechanism by which complex I
deficient fibroblasts maintain Dw under unstimulated condi-
tions remains to be elucidated. One possibility is that complex
V of the OXPHOS system acts in the reversed mode and uses
glycolytic ATP in order to maintain Dw. The other possibility is
that the activity of the electron transport chain is sufficient to
maintain Dw despite the presence of a first complex with a
significantly reduced enzymatic activity. In the latter case, full
restoration of the Bk-induced increase in [ATP]M either means
that complex II takes over the role of complex I as entry point
of reducing equivalents, or that the increase in [Ca2+]M directly
or indirectly increases the activity of complex V.Indeed, recent work has shown that Ca2+ can increase the
activity of complex V in homogenates of cultured skin
fibroblasts [12] and heart and skeletal muscle biopsy material
of healthy children [6,13]. In agreement with our findings, the
stimulatory effect of Ca2+ on the activity of complex V was
found to be decreased in fibroblasts from children with defects
in the different respiratory chain complexes [37]. Other studies
suggest that Ca2+ can increase the activity of the adenine
nucleotide translocase (ANT), involved in the electrogenic
exchange of ADP3 for ATP4 across the IMM, on the external
side of the IMM [16]. Similarly, it has been suggested that the
aspartate/glutamate carrier (AGC), which is important in the
aspartate/malate shuttle that imports NADH into the mitochon-
dria, is stimulated by external Ca2+ [14]. Accordingly, over-
expression of this carrier in Chinese hamster ovary cells
increased the amplitude of the agonist-induced peak increase
in [ATP]M, independent of the activation of the Ca
2+-sensitive
matrix dehydrogenases [15]. In principle, all three mechan-
isms can explain the reduced Bk-induced increase in [ATP]M
in human complex I deficiency. The reduced increase in
[Ca2+]M can lead to reduced activation of complex V, whereas
the reduced increase in [Ca2+]C can lead to reduced activation
of the ANT and/or AGC. However, our recent finding that the
inhibitor of Na+–Ca2+ exchange CGP 37157 (1 AM, 2 min)
can fully restore the Bk-induced increases in [Ca2+]M and
[ATP]M, without restoring the Bk-induced increase in [Ca
2+]C
argues against the latter increase being rate-limiting in Ca2+-
stimulated mitochondrial ATP production in a patient fibro-
blast cell line [4]. Given the literature that is presently
available, this leaves the possibility of the Ca2+-dependent
activation of complex V being rate-limiting in human
complex I deficiency.
Based on our findings, we propose the following model to
explain the reduced agonist-induced increase in mitochondrial
ATP production in fibroblasts harbouring pathological defects
in nuclear-encoded subunits of complex I. In a presently
unknown manner (for further discussion see below), malfunc-
tioning of complex I of the mitochondrial electron transport
chain leads to a reduction in ER Ca2+ content. As a
consequence, Ca2+ mobilizing agonists, which act through
IP3, release less Ca
2+ from the ER, leading to a reduced
increase in [Ca2+]C. This, in turn, leads to a reduced increase in
mitochondrial Ca2+ uptake and thus to a reduced increase in
[Ca2+]M. Due to this reduced increase in [Ca
2+]M, the activity
of complex V will be less increased, leading to a decreased
production of ATP and thus to a reduced increase in [ATP]M.
The ATP that is produced is rapidly released into the Fsynaptic_
clefts between juxtaposed ER and mitochondria [38], where it
is used to speed-up the rate of cytosolic Ca2+ removal by the
SERCA. All 10 patient fibroblasts with a reduced Bk-induced
increase in [ATP]M showed a significantly decreased cytosolic
Ca2+ removal rate, indicating that a reduction in mitochondrial
ATP release leads to a reduced increase in SERCA activity and
thus to a reduced speeding-up of the cytosolic Ca2+ removal
rate.
As to the link between the reduced enzymatic activity of
complex I and the reduced Ca2+ content of the ER, one can
H.-J. Visch et al. / Biochimica et Biophysica Acta 1762 (2006) 115–123122speculate that this involves the increased production of
superoxide anion-derived radicals such as hydrogen peroxide.
In agreement with this idea, treatment of WEH17.2 lymphoid
cells with hydrogen peroxide significantly reduced the amount
of thapsigargin-releasable Ca2+ [39]. Furthermore, evidence
has been provided that superoxide levels are indeed increased
in fibroblasts derived from complex I deficient patients [40].
We recently showed that mitochondrial morphology is
significantly but to a variable degree altered in complex I
deficient patient fibroblasts [41]. Recent work by Rizzuto and
co-workers has indicated that such alterations may affect the
process of Ca2+ stimulated mitochondrial ATP production [42].
We also showed that inhibition of the activity of complex I by
its specific inhibitor rotenone results in increased levels of lipid
peroxidation in healthy fibroblasts [43]. This opens the
possibility that lipid peroxidation products interact with
processes involved in regulating the ER Ca2+ content.
According to the above model, all five parameters (ER Ca2+
content, BK-induced increases in [Ca2+]C, [Ca
2+]M and [ATP]M
and cytosolic Ca2+ removal rate) were significantly decreased
in 6 out of the 14 patient cell lines tested. The cell lines in
question are from the patients P1, P5, P9, P11, P12 and P13
(enzymatic complex I activities of 31%, 26%, 36%, 68%, 18%
and 64% of the lowest control, respectively) (Table 1).
Remarkably, in four out of the 14 patient, cell lines tested
neither the ER Ca2+ content nor the Bk-induced increase in
[Ca2+]C, [Ca
2+]M or [ATP]M differed significantly from control.
However, in all four patients the enzymatic activity of complex
I was significantly decreased (residual activities of 39%, 87%,
75% and 73% for P4, P6, P7 and P14, respectively). The
importance of this finding is that these four patients cell lines
might provide the key to elucidating the link between the
reduced enzymatic activity of complex I and the decreased
Ca2+ content of the ER. In P3 (residual activity of 36%), both
the ER Ca2+ content and the Bk-induced increase in [Ca2+]C
were not different from control, whereas the Bk-induced
increases in [Ca2+]M and [ATP]M were significantly reduced.
Finally, [Ca2+]C and [Ca
2+]M did not significantly differ from
control in P2 (residual activity of 40%) and P10 (residual
activity of 53%), respectively. These patients may provide
additional information on other processes than described in our
model interfering with Ca2+-stimulated mitochondrial ATP
production.
The relationship between the Bk-induced peak increases in
[Ca2+]M and [ATP]M, determined in the whole cohort of
patient fibroblasts, was best described by a sigmoid function
with k and n values of 78T0.07% and 11T0.11, respectively.
This means that the peak increase in [ATP]M is half-maximal
at a peak increase in [Ca2+]M of 78% of its maximum. The
high n value reflects the high degree of cooperativity between
the peak increases in [Ca2+]M and [ATP]M. As can be
deduced from Fig. 2B, this means that [ATP]M hardly
increases when the peak increase in [Ca2+]M remains below
¨50% of its maximum, whereas above this value the
dependence of [ATP]M on [Ca
2+]M will be very steep. A
similar k-value (¨70%) was found for HeLa cells when the
hormone-induced peak increase in [Ca2+]M was lowered bygradual depletion of the ER Ca2+ content [3]. The latter
finding is in agreement with the present conclusion that a
reduction in ER Ca2+ content underlies the reduced peak
increases in [Ca2+]C, [Ca
2+]M and [ATP]M in the complex I-
deficient patient fibroblasts.
5. Conclusions
In this study, we show that primary skin fibroblasts of
patients with an isolated complex I deficiency display various
degrees of ER Ca2+ filling. Moreover, we show that the degree
of ER Ca2+ filling is directly related to the Bk-induced peak
increase in [ATP]M, which, in turn, is directly related to the
degree to which the rate of cytosolic Ca2+ removal is speeded
up. This finding provides new possible drug targets for the
amelioration of the condition of patients suffering from isolated
complex I deficiency.
Acknowledgements
This work was supported by an equipment grant of
NWO (Netherlands Organization for Scientific Research,
No: 911-02-008) and the European Community’s sixth
Framework Programme for Research, Priority 1 ‘‘Life sciences,
genomics and biotechnology for health’’, contract number
LSHM-CT-2004-503116.
References
[1] M.R. Duchen, Mitochondria in health and disease: perspectives on a new
mitochondrial biology, Mol. Aspects Med. 25 (2004) 365–451.
[2] R. Rizzuto, A.W. Simpson, M. Brini, T. Pozzan, Rapid changes of
mitochondrial Ca2+ revealed by specifically targeted recombinant
aequorin, Nature 358 (1992) 325–327.
[3] L.S. Jouaville, P. Pinton, C. Bastianutto, G.A. Rutter, R. Rizzuto,
Regulation of mitochondrial ATP synthesis by calcium: evidence for a
long-term metabolic priming, Proc. Natl. Acad. Sci. U. S. A. 96 (1999)
13807–13812.
[4] H.J. Visch, G.A. Rutter, W.J.H. Koopman, J.B. Koenderink, S.
Verkaart, T. de Groot, A. Varadi, K.J. Mitchell, L.P. van den Heuvel,
J.A.M. Smeitink, P.H.G.M. Willems, Inhibition of mitochondrial
Na+/Ca2+ exchange restores agonist-induced ATP production and
Ca2+ handling in human complex I deficiency, J. Biol. Chem. 279
(2004) 40328–40336.
[5] D.G. Nicholls, S. Vesce, L. Kirk, S. Chalmers, Interactions between
mitochondrial bioenergetics and cytoplasmic calcium in cultured cere-
brellar granule cells, Cell Calcium. 34 (2003) 407–424.
[6] A.M. Das, Regulation of mitochondrial ATP-synthase in health and
disease, Mol. Genet. Metab. 79 (2003) 71–82.
[7] B. Korzeniewski, The modeling of oxidative phosphorylation in skeletal
muscle, Jpn. J. Physiol. 54 (2004) 511–516.
[8] J.G. McCormack, A.P. Halestrap, R.M. Denton, Role of calcium ions in
the regulation of mammalian intramitochondrial metabolism, Physiol.
Rev. 70 (1990) 391–425.
[9] G.A. Rutter, Ca2+-binding to citrate cycle dehydrogenases, Int. J.
Biochem. 22 (1990) 1081–1088.
[10] G. Hajno´czky, L.D. Robb-Gaspers, M.B. Seitz, A.P. Thomas, Decoding
of cytosolic calcium oscillations in the mitochondria, Cell 85 (1995)
415–424.
[11] L.D. Robb-Gaspers, P. Burnett, G.A. Rutter, R.M. Denton, R. Rizutto,
A.P. Thomas, Integrating cytosolic calcium signals into mitochondrial
metabolic responses, EMBO J. 17 (1998) 4987–5000.
H.-J. Visch et al. / Biochimica et Biophysica Acta 1762 (2006) 115–123 123[12] A.M. Das, D.J. Byrd, J. Brodehl, Regulation of the mitochondrial ATP-
synthase in human fibroblasts, Clin. Chim. Acta 231 (1994) 61–68.
[13] A.M. Das, Regulation of mitochondrial ATP synthase activity in human
myocardium, Clin. Sci. (Lond.) 94 (1998) 499–504.
[14] L. Palmieri, B. Pardo, F.M. Lasorsa, A. del Arco, K. Kobayashi, M. Iijima,
M.J. Runswick, J.E. Walker, T. Saheki, J. Satrustegui, F. Palmieri, Citrin
and aralar1 are Ca2+-stimulated aspartate/glutamate transporters in
mitochondria, EMBO J. 20 (2001) 5060–5069.
[15] F.M. Lasorsa, P. Pinton, L. Palmieri, G. Fiermonte, R. Rizzuto, F.
Palmieri, Recombinant expression of the Ca2+-sensitive aspartate/gluta-
mate carrier increases mitochondrial ATP production in agonist-stimulated
Chinese hamster ovary cells, J. Biol. Chem. 278 (2003) 38686–38692.
[16] T.E. Gunter, D.I. Yule, K.K. Gunter, R.A. Eliseev, J.D. Salter, Calcium
and mitochondria, FEBS Lett. 567 (2004) 96–102.
[17] J.A.M. Smeitink, L.P. van den Heuvel, S. DiMauro, The genetics and
pathology of oxidative phosphorylation, Nat. Rev., Genet. 2 (2001)
342–352.
[18] J.A.M. Smeitink, S. Sengers, F. Trijbels, L.P. van den Heuvel, Human
NADH:ubiquinone oxidoreductase, J. Bioenerg. Biomembr. 33 (2001)
259–266.
[19] R. Vogel, L. Nijtmans, C. Ugalde, L.P. van den Heuvel, J.A.M. Smeitink,
Complex I assembly: a puzzling problem, Curr. Opin. Neurol. 17 (2004)
179–186.
[20] J. Hirst, J. Carroll, I.M. Fearnely, R.J. Shannon, J. Walker, The nuclear
encoded subunits of complex I from bovine heart mitochondria, Biochim.
Biophys. Acta 1604 (2003) 135–150.
[21] J.A.M. Smeitink, L.P. van den Heuvel, Human mitochondrial complex I in
health and disease, Am. J. Hum. Genet. 64 (1999) 1505–1510.
[22] P. Benit, D. Chretien, N. Kadhom, P. de Lonlay-Debeney, V. Cormier-
Daire, A. Cabral, S. Peudenier, P. Rustin, A. Munnich, A. Rotig, Large-
scale deletion and point mutations of the nuclear NDUFV1 and NDUFS1
genes in mitochondrial complex I deficiency, Am. J. Hum. Genet. 68
(2001) 1344–1352.
[23] P. Benit, A. Slama, F. Cartault, I. Giurgea, D. Chretien, S. Lebon, C.Marsac,
A.Munnich, A. Rotig, P. Rustin,Mutant NDUFS3 subunit of mitochondrial
complex I causes Leigh syndrome, J. Med. Genet. 41 (2004) 14–17.
[24] D.M. Kirby, R. Salemi, C. Sugiana, A. Ohtake, L. Parry, K.M. Bell, E.P.
Kirk, A. Boneh, R.W. Taylor, H.H. Dahl, M.T. Ryan, D.R. Thorburn,
NDUFS6 mutations are a novel cause of lethal neonatal mitochondrial
complex I deficiency, J. Clin. Invest. 114 (2004) 837–845.
[25] C. Ugalde, R.J. Janssen, L.P. van den Heuvel, J.A.M. Smeitink, L.G.
Nijtmans, Differences in assembly or stability of complex I and other
mitochondrial OXPHOS complexes in inherited complex I deficiency,
Hum. Mol. Genet. 13 (2004) 659–667.
[26] J.L. Loeffen, O. Elpeleg, J.A.M. Smeitink, R. Smeets, S. Sto¨ckler-
Ipsiroglu, H. Mandel, R. Sengers, F. Trijbels, L.P. van den Heuvel,
Mutations in the complex I NDUFS2 gene of patient with cardiomyopathy
and encephalomyopathy, Ann. Neurol. 49 (2001) 195–201.
[27] L.P. van den Heuvel, W. Ruitenbeek, R. Smeets, Z. Gelman-Kohan, O.
Elpeleg, J. Loeffen, F. Trijbels, E. Mariman, D. de Bruijn, J.A.M.
Smeitink, Demonstration of a new pathogenic mutation in human complex
I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD
(AQDQ) subunit, Am. J. Hum. Genet. 62 (1998) 262–268.
[28] S.M. Budde, L.P. van den Heuvel, A.J. Janssen, R.J. Smeets, C.A.
Buskens, L. DeMeirleir, R. van Coster, M. Baethmann, T. Voit, J.M.
Trijbels, J.A. Smeitink, Combined enzymatic complex I and III deficiency
associated with mutations in the nuclear encoded NDUFS4 gene,
Biochem. Biophys. Res. Commun. 275 (2000) 63–68.[29] R.H. Triepels, L.P. van den Heuvel, J.L. Loeffen, C.A. Buskens, R.J.
Smeets, M.E. Rubio Gozalbo, E.C. Mariman, F.A. Wijburg, P.G. Barth,
J.M. Trijbels, J.A.M. Smeitink, Leigh syndrome associated with a
mutation in the NDUFS7 (PSST) nuclear encoded subunit of complex I,
Ann. Neurol. 45 (1999) 787–790.
[30] M. Schuelke, J.A.M. Smeitink, E. Mariman, J. Loeffen, B. Plecko, F.
Trijbels, S. Sto¨ckler-Ipsiroglu, L.P. van den Heuvel, Mutant NDUFV1
subunit of complex I causes leukodystrophy and myoclonic epilepsy, Nat.
Genet. 21 (1999) 260–261.
[31] E.K. Ainscow, G.A. Rutter, Mitochondrial priming modifies Ca2+
oscillations and insulin secretion in pancreatic islets, Biochem. J. 353
(2001) 175–180.
[32] V.A. Luckow, S.C. Lee, G.F. Barry, P.O. Olins, Efficient generation of
infectious recombinant baculoviruses by site-specific transposon-mediated
insertion of foreign genes into a baculovirus genome propagated
Escherichia coli, J. Virol. 67 (1993) 4566–4579.
[33] M. Brini, R. Marsault, C. Bastianutto, C. Alvarez, T. Pozzan, R.
Rizzuto, Transfected aequorin in the measurement of cytosolic Ca2+
concentration ([Ca2+]C), A critical evaluation, J. Biol. Chem. 270 (1995)
9896–9903.
[34] F.H. van de Put, J.J.H.H.M. De Pont, P.H.G.M. Willems,
Heterogeneity between intracellular Ca2+ stores as the underlying
principle of quantal Ca2+ release by inositol 1,4,5-trisphosphate in
permeabilized pancreatic acinar cells, J. Biol. Chem. 269 (1993)
12438–12443.
[35] W.J.H. Koopman, R.R. Bosch, S.E. van Emst-de Vries, M. Spaargaren,
J.J.H.H.M. De Pont, P.H.G.M. Willems, R-Ras alters Ca2+ homeostasis
by increasing the Ca2+ leak across the endoplasmic reticular membrane,
J. Biol. Chem. 278 (2003) 13672–13679.
[36] A.J.C. de Groof, J.A. Fransen, R.J. Errington, P.H.G.M. Willems, B.
Wieringa, W.J.H. Koopman, The creatine kinase system is essential for
optimal refill of the sarcoplasmic reticulum Ca2+ store in skeletal muscle,
J. Biol. Chem. 277 (2002) 5275–5278.
[37] A.M. Das, K. Ullrich, Dysregulation of the mitochondrial ATP-synthase in
respiratory chain defects: first experience, J. Inherit. Metab. Dis. 21 (1998)
220–223.
[38] R. Rizzuto, M.R. Duchen, T. Pozzan, Flirting in little space: the
ER/mitochondria Ca2+ liaison, Sci. STKE 13 (2004 (Jan)) 215, (re1).
[39] C.W. Distelhorst, M. Lam, T.S. McCormick, Bcl-2 inhibits hydrogen
peroxide-induced ER Ca2+ pool depletion, Oncogene 12 (1996)
2051–2055.
[40] S. Pitka¨nen, B.H. Robinson, Mitochondrial complex I deficiency leads to
increased production of superoxide radicals and induction of superoxide
dismutase, J. Clin. Invest. 98 (1996) 345–351.
[41] W.J.H. Koopman, H.J. Visch, S. Verkaart, L.P. van den Heuvel, J.A.M.
Smeitink, P.H.G.M. Willems, Mitochondrial network complexity and
pathological decrease in complex I activity are tightly correlated in
isolated human complex I deficiency, Am. J. Physiol., Cell Physiol.
289 (2005) C881–C890.
[42] G. Szabadkai, A.M. Simoni, M. Chami, M.R. Wieckowski, R.J. Youle, R.
Rizzuto, Drp-1-dependent division of the mitochondrial network blocks
intraorganellar Ca2+ waves and protects against Ca2+-mediated apoptosis,
Mol. Cell 16 (2004) 59–68.
[43] W.J.H. Koopman, S. Verkaart, H.J. Visch, F.H. van der Westhuizen, M.P.
Murphy, L.P. van den Heuvel, J.A.M. Smeitink, P.H.G.M. Willems,
Inhibition of complex I of the electron transport chain causes O2
-mediated
mitochondrial outgrowth, Am. J. Physiol., Cell Physiol. 288 (2005)
C1440–C1450.
